NxStage Medical (NXTM) is a medical device company in the dialysis therapy market that develops, manufactures and markets innovative products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. It is a smaller company in the market compared to established players, such as Fresenius (FMS) and DaVita (DVA). These two companies account for more than half of the conventional dialysis market segment in the United States. However, NxStage Medical's System One is currently the only portable system specifically indicated for use in the home hemodialysis market segment in the United States.
NXTM debuted in the stock market in late 2005. In 2011 NXTM crossed $25 before witnessing a secular...
Only subscribers can access this article, which is part of the PRO research library covering 3,775 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: